Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma

Abstract

BackgroundChromograninA in prostate carcinoma (PC) indicate NE differentiation. This tumour is more aggressive and resistant to hormone therapy.Patients and methodsWe analyzed the incidence of pre-operative ChromograninA serum levels in non metastatic PC patients. Serum PSA and ChromograninA were analyzed before treatment. Clinicopathological parameters were evaluated in relation to serum ChromograninA. 486 patients were enrolled.ResultsWe found 352 pT2 and 134 pT3. 21 patients were N+. 278 patients had Gleason score levels <7; 173 patients had levels = 7 (122 were 3+4 and 51 4+3); and 35 patients with levels >7. Median PSA pre-operative level was 7.61 ng/ml. PSA was significantly associated with pT stage (pT2 with PSA abnormal 23.6% vs pT3 48.5%, p < 0.0001) and with a Gleason score (PSA abnormal 60% in the Gleason score was >7 vs 29.5% in the Gleason score = 7 vs 27.3% in the Gleason score <7, p < 0.0001). In 114 patients pre-operative ChromograninA levels were elevated (23.5%). Serum ChromograninA levels had no significant association with PSA (p = 0.44) and pT stage (p = 0.89). abnormal ChromograninA levels increased from a Gleason score of <7 (25.5%) to >7 (31.4%) (p = 0.12). The serum ChromograninA levels in the two groups of patients were subdivided before and after 2005 on the basis of different used assays, showing no correlation with serum ChromograninA and other parameters.ConclusionsThis study showed that ChromograninA levels correlated to NE differentiation and possible aggressiveness of PC. Pre-operative circulating ChromograninA could complement PSA in selecting more aggressive PC cases, particularly in the presence of a higher Gleason score. Complementary information is provided by the absence of a correlation between serum ChromograninA and PSA levels.

Brachyury identifies a class of enteroendocrine cells in normal human intestinal crypts and colorectal cancer

“…ChgA signals have been linked to tumour aggressiveness in prostate cancer, where the presence of proteins/hormones produced from neuroendocrine cells may act as growth factors contributing to paracrine effects on surrounding stromal cells [ 27 ]. Furthermore, CRCs displaying endocrine differentiation have been reported to have a worse prognosis [ 13 ].…”

Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

“…[25] Some studies have claimed that CgA is an independent prognostic marker for PCa, [40] while others have conflicted with these findings. [29,41] No PCa predictive values were seen for IGF-1, IGFBP-3 or CgA; AUC were 0.58, 0.55 and 0.56, respectively. Similarly, some earlier reports found disappointing results for these biomarkers.…”

Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors

“…Importantly, neuropeptides released from the NE prostate cancer cells may appear in the circulation [ 6 ]. These serum markers have recently attracted considerable attention for their ability to monitor disease [ 6 , 11 ] and predict survival [ 12 , 13 ]. NE serum markers have been suggested as beneficial surrogates for tumor burden [ 6 ] and mirror prostate cancer progression when raising.…”